Resources

MDoutlook® Delivers Precision Intelligence

After every major conference, MDoutlook provides valuable insights on the impact of new data presented. In our 3rd OncoPoll™ study following the 2019 ASCO conference, we looked at the oral presentations in CLL and researched how US and EU5 oncologists evaluated them. Even with these CLL presentations being on the
Read more
After every major conference, MDoutlook provides valuable insights on the impact of new data presented. In our 2nd OncoPoll™ study following the 2019 ASCO conference, we researched what US and EU5 oncologists thought about a number of new agents being developed that target specific driver mutations in small populations of
Read more
After every major conference, MDoutlook provides valuable insights on the impact of new data presented. At the 2019 ASCO conference, prostate cancer was one of the hottest areas, and our 1st independent OncoPoll™ study researched how clinicians will be treating the non-metastatic castration-resistant and the metastatic hormone-sensitive prostate cancer (nmCRPC
Read more
Identifying the right expert at the right time is often a challenge for many life sciences companies and their agencies. What if there would be a short-cut (with no compromises!) to gain precision engagement with ThoughtLeaders and related treaters? At MDoutlook, we help you tap into the expertise of over
Read more
With the deluge of scientific data presentations at a conference, it is very competitive for life science companies to break through the noise and assess impact. By evaluating whether announcements change oncologists’ behavior, we can estimate how a data presentation influences their future treatment decisions and clinical practice. Clients often
Read more
Rare cancers feature more prominently at this year’s conference season, and ASCO has named "Progress in Treating Rare Cancers" as their advance of the year. We are especially poised to gauge the reactions of oncologists to the new developments in rare cancers and understanding standard treatment practices if they exist
Read more
MDoutlook is continuing its fast growth path. To support our growth, and overall client services and experience, we are keen to add a Manager, Strategic Development to our team at our headquarters in greater Atlanta. Playing a vital supportive role initially within our business, we look to expand the role
Read more
Biomarkers are embraced by oncologists as an important tool in their arsenal to treat cancer. They enable a more personalized approach to treatment by identifying patients who are likely to respond to specific immunotherapies and yet oncologists want pharma to do more. In our 2019 Leadership study, we asked oncologists
Read more
Oncologists have no clear leader when asked about the supportive services and tools provided to them by pharmaceutical companies. Our 2019 Leadership study in ImmunoOncology (IO) explored oncologists’ views across multiple engagement channels ranging from digital support solutions (e.g. apps) to more traditional activities such as educational learning. HealthCare Provider
Read more
Financial impact and affordability of medicines is the number one concern for oncologists in our 2019 Leadership research in ImmunoOncology. Oncologists were asked to choose their top three areas (from a list of fourteen attributes) for corporate leaders to improve most over the next few years. The sentiment is especially
Read more
After every major conference, MDoutlook provides valuable insights on the impact of new data presented. In our 3rd OncoPoll™ study following the 2019 ASCO conference, we looked at the oral presentations in CLL and researched how US and EU5 oncologists evaluated them. Even with these CLL presentations being on the
Read more
After every major conference, MDoutlook provides valuable insights on the impact of new data presented. In our 2nd OncoPoll™ study following the 2019 ASCO conference, we researched what US and EU5 oncologists thought about a number of new agents being developed that target specific driver mutations in small populations of
Read more
After every major conference, MDoutlook provides valuable insights on the impact of new data presented. At the 2019 ASCO conference, prostate cancer was one of the hottest areas, and our 1st independent OncoPoll™ study researched how clinicians will be treating the non-metastatic castration-resistant and the metastatic hormone-sensitive prostate cancer (nmCRPC
Read more
Identifying the right expert at the right time is often a challenge for many life sciences companies and their agencies. What if there would be a short-cut (with no compromises!) to gain precision engagement with ThoughtLeaders and related treaters? At MDoutlook, we help you tap into the expertise of over
Read more
With the deluge of scientific data presentations at a conference, it is very competitive for life science companies to break through the noise and assess impact. By evaluating whether announcements change oncologists’ behavior, we can estimate how a data presentation influences their future treatment decisions and clinical practice. Clients often
Read more
Rare cancers feature more prominently at this year’s conference season, and ASCO has named "Progress in Treating Rare Cancers" as their advance of the year. We are especially poised to gauge the reactions of oncologists to the new developments in rare cancers and understanding standard treatment practices if they exist
Read more
MDoutlook is continuing its fast growth path. To support our growth, and overall client services and experience, we are keen to add a Manager, Strategic Development to our team at our headquarters in greater Atlanta. Playing a vital supportive role initially within our business, we look to expand the role
Read more
Biomarkers are embraced by oncologists as an important tool in their arsenal to treat cancer. They enable a more personalized approach to treatment by identifying patients who are likely to respond to specific immunotherapies and yet oncologists want pharma to do more. In our 2019 Leadership study, we asked oncologists
Read more
Oncologists have no clear leader when asked about the supportive services and tools provided to them by pharmaceutical companies. Our 2019 Leadership study in ImmunoOncology (IO) explored oncologists’ views across multiple engagement channels ranging from digital support solutions (e.g. apps) to more traditional activities such as educational learning. HealthCare Provider
Read more
Financial impact and affordability of medicines is the number one concern for oncologists in our 2019 Leadership research in ImmunoOncology. Oncologists were asked to choose their top three areas (from a list of fourteen attributes) for corporate leaders to improve most over the next few years. The sentiment is especially
Read more